Skip to main content
Caplight Logo









Quanta Therapeutics

Quanta Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.quantatx.com/

Last Round

Series D

Jun 24, 2026

Total Funding Raised

$174.7M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Quanta Therapeutics is a biotechnology company that develops oral small molecule therapeutics for RAS-driven cancers using a proprietary Second Harmonic Generation optical platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

KRAS inhibitoroncologytargeted therapysmall-molecule drugRAS-driven cancerbiotechdrug discoveryclinical-stage biotechprecision medicinecancer drugdrug pipelinebiopharmaclinical trialdrug resistancemedicinal chemistry

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Quanta Therapeutics Comparables

Compare Quanta Therapeutics with similar companies based on industry and business-model similarity.

Quanta Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Kumquat Biosciences
85%
BridgeBio Pharma, Inc.
85%
Kestrel Therapeutics
85%

Quanta Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DJun 24, 2026
Series DMay 22, 2023
Series COct 26, 2021
Series ASep 5, 2018

Key People

Founding team and executive leadership

Vanessa Jacoby

Chief Business Officer And Chief Financial Officer

Executive Team

Quanta Therapeutics Investors

Notable investors and investment history

Quanta Therapeutics investors
InvestorRounds
Longitude CapitalSeries D, Series C
Surveyor CapitalSeries D, Series C
Avidity Partners ManagementSeries D
Vida VenturesSeries D, Series B, Series C
Avidity PartnersSeries D
WS Investment CompanySeries D
Logos CapitalSeries B, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 24, 2026

    $76M round completed.

  • Oct 24, 2025

    Presenting first clinical data for drug candidate QTX3034 at AACR-NCI-EORTC conference.

Quanta Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Quanta Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Quanta Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range34
Year Founded2018
Last FundingJun 24, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?